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Hypofractionated postoperative radiotherapy [RT] (2) is now  the 
standard of care for virtually all patients with  early breast cancer 
requiring adjuvant RT. This has been practice changing worldwide 
except in the USA where there is more caution on the generalisability 
of  level 1 evidence (3). Current research focuses on identifying the 
limits of hypofractionation. The UK FAST trial compared two dose 
levels (5.7 Gy and 6.0Gy) of a 5 fraction regime giving one 
fraction/week with a control schedule of 50 Gy in 25 fractions (4). 
Moderate/marked adverse effects were greater with 30 Gy compared 
to 50 Gy but similar with 28.5 Gy. The FAST FORWARD trial (5) is 
comparing two 5 fractions regimens (27 Gy [5.4Gy/fr] and 26 Gy [5.2 
Gy/fr) over a week with a standard 3 week schedule. Access to 
intensity modulated RT (IMRT) has permitted delivery of a 
simultaneous integrated breast boost to the site of excision and is the 
subject  of ongoing trials (6,7) 
There is  controversy over the role of axillary nodal RT in patients 
with a positive sentinel node biopsy. (SLNB). Traditionally axillary  
lymph node dissection (ALND) has been the standard treatment for 
SNLB patients with early breast cancer, even for a single 
micrometastasis.  
The role of ALDN in early breast cancer was examined in the ACOSOG 
Z11 trial (8). SNLB positive patients after breast conserving surgery 
(BCS) were randomised to ALDN or no further RT if they were node 
positive. Unfortunately the trial did not reach its target accrual for 
which it was powered. There was no difference in regional recurrence 
or DFS. Some have concluded that ALDN may not be necessary, even 
for a SLN macrometastasis. Others have argued that the lack of QA of 
axillary RT in the trial may have obscured any tendency to place the 
upper border of the tangent fields higher in the  SNLB alone arm of 
the trial (‘high tangents’)  to cover level 1-11 axillary nodes. However 
more recent studies suggest that ‘high tangents’ are unlikely to 
deliver a cancericidal dose, even to the lower axillary nodes.  
Regional nodal irradiation (RNI) is an alternative to ALND for  SNLB 
positive patients. Its role is being investigated in the AMAROS trial (9)  
in women with any number or size of positive SLNs after BCS or 
mastectomy. Patients are randomised to ALDN or axillary RT. Accrual 
is complete and results are awaited. The NCIC-CTG MA20 trial 
evaluated RNI in high risk pN0 or pN1 patients in addition to whole 
breast RT after BCS and ALND (10). There was a 1.6% gain in OS from 
the addition of RNI and a 5.7% benefit in DFS. The downside was a 
1.1% increase in pneumonitis and 3.2% increase in lymphoedema. 
At present practice varies in the selection of patients for axillary RT 
after a positive SLNB. Regional recurrence rates after ALND or RNI 
may be low at 1-2%. RNI carries a lower risk of lymphoedema than 
ALDN but a higher risk of impaired shoulder function.  The POSNOC 
trial plans to examine the role of RNI in low volume axillary disease. 
The hypothesis of the trial is that clinically and ultrasound axillary 
node negative patients with 1-2 involved SLN macrometastases would 
have non inferior clinical outcomes whether randomised to axillary RT 
orto ALND (11). The primary endpoint of the trial is axillary 
recurrence at 5 years. The trial will be subject to an RT quality 
assurance programme. 
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Chemotherapy and radiotherapy associations have improved the 
prognosis of  most cancers. Their role for breast cancers is evolving. In 
the adjuvant setting, three phase III randomised trials, and several 
retrospective studies, suggested the benefit of chemoradiotherapy, 
especially for locally advanced breast cancers, at the cost of 
increased acute and late toxicities and poorer cosmetic effects. The 
benefit of new regimens of chemoradiotherapy need to be evaluated. 
In the neoadjuvant setting, breast chemoradiotherapy should permit 
to increase the breast conservation rate, while its administration in 
rescue after failure of neoadjuvant chemotherapy could enable 
surgical procedure. A better knowledge of the cancer biology would 
be worth incorporating into therapeutic strategies in order to better 
determine the need for chemoradiotherapy and its modalities for 
breast cancers. 
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Purpose/Objective: Intensity modulated radiotherapy (IMRT) im-
proves dose homogeneity across the breast. However, there is little 
randomised controlled trial data to confirm that improved homogenei-
ty with IMRT decreases late breast tissue toxicity. The Cambridge 
Breast IMRT trial investigated this hypothesis and the 5 year results 
are reported. 
Materials and Methods: The standard tangential plans of 1145 unse-
lected trial patients were analysed. 815 (71%) patients had inhomoge-
neous plans (≥ 2 cm3 receiving 107% of the prescribed dose: 40 Gy in 
15 fractions over 3 weeks) and were randomised to standard radiothe-
rapy (RT) or re-planned with forward planned IMRT. Late breast tissue 
toxicities were assessed at 5 years using validated methods: photo-
graphic assessment (overall cosmesis and breast shrinkage compared 
to baseline pre-RT photographs) and clinical assessment (telengiecta-
sia, induration, oedema and pigmentation). The difference in these 
endpoints between randomised groups was analysed using polycho-
tomous logistic regression. Data from all trial patients were also used 
to assess the effect of baseline (pre-RT) surgical cosmesis on these 
late toxicity endpoints. 
Results: The late normal tissue toxicity outcome at 5 years was 
available for 654/1145 (57%) and 465/815 (57%) for all patients and 
randomised patients respectively. On univariate analysis, fewer 
patients in the IMRT group developed skin telengiectasia (OR 0.58, 
95% CI 0.36-0.92; p=0.02) and sub-optimal overall cosmesis (OR 0.67, 
95% CI 0.48-0.96; p=0.027) compared with patients receiving standard 
RT. No significant difference was seen for photographically assessed 
breast shrinkage, breast oedema, tumour bed induration and pigmen-
tation between the two groups. The benefit of IMRT over standard RT 
was maintained on multivariate analysis for both skin telengiectasia 
(p=0.031) and overall cosmesis (p=0.038). Patients with poor baseline 
